Objective: To investigate the effects of increased alpha-linolenic acid (ALA)-intake on intima-media thickness (IMT), oxidized low-density lipoprotein (LDL) antibodies, soluble intercellular adhesion molecule-1 (sICAM-1), C-reactive protein (CRP), and interleukins 6 and 10. Design: Randomized double-blind placebo-controlled trial. Subjects: Moderately hypercholesterolaemic men and women (55710 y) with two other cardiovascular risk factors (n ¼ 103). Intervention: Participants were assigned to a margarine enriched with ALA (fatty acid composition 46% LA, 15% ALA) or linoleic acid (LA) (58% LA, 0.3% ALA) for 2 y. Results: Dietary ALA intake was 2.3 en% among ALA users, and 0.4 en% among LA users. The 2-y progression rate of the mean carotid IMT (ALA and LA: þ 0.05 mm) and femoral IMT (ALA: þ 0.05 mm; LA: þ 0.04 mm) was similar, when adjusted for confounding variables. After 1 and 2 y, ALA users had a lower CRP level than LA users (net differences À0.53 and À0.56 mg/l, respectively, Po0.05). No significant effects were observed in oxidized LDL antibodies, and levels of sICAM-1, interleukins 6 and 10. Conclusions: A six-fold increased ALA intake lowers CRP, when compared to a control diet high in LA. The present study found no effects on markers for atherosclerosis. Sponsorship: The Dutch 'Praeventiefonds'.
Introduction
The standard dietary advice for hypercholesterolaemic persons is to decrease the intake of saturated fat, either by reducing total fat intake or by partial replacement with unsaturated fatty acids or carbohydrates (National Cholesterol Education Program, 2001 ). The predominant polyunsaturated fatty acid in the Western diet is the n-6 fatty acid linoleic acid (LA: 18:2n-6) (Sanders, 2000) , which has an established lipid-lowering effect (Schaefer, 1997) . However, an excess intake of LA may have serious long-term side effects that influence the development of chronic diseases (Berry, 2001 ). An increased intake of n-3 polyunsaturated fatty acids may be less atherogenic than the n-6 fatty acids (von Schacky, 2000) . Potential mechanisms of action include a decreased response of platelets to aggregation (Freese et al, 1994) , a lower concentration of serum triacylglycerol (Schmidt et al, 1993) , and a decreased vascular smooth muscle cell proliferation (Pakala et al, 1999) . Furthermore, n-3 fatty acids may have anti-inflammatory effects, possibly by affecting cytokine synthesis (Endres, 1996; Mantzioris et al, 2000; De Caterina & Basta, 2001) .
In secondary prevention studies, both alpha-linolenic acid (ALA: 18:3n-3), which is a short-chain n-3 fatty acid, and fish (rich in long-chain n-3 fatty acids) have been suggested to prevent the recurrence of cardiac events (de Lorgeril et al, 1994; Marchioli et al, 2001) . A short-term study found beneficial effects of increased ALA intake on C-reactive protein (CRP) and interleukin-6 (Rallidis et al, 2003) . However, the effects of long-term increased ALA intake on atherogenic and inflammatory markers have as yet not been investigated (von Schacky, 2000; Rallidis et al, 2003) . In our prevention project for coronary heart disease (CHD), subjects at high risk for CHD were randomly and double-blindly allocated to an ALA-enriched or an LA-rich margarine during 2 y. We assessed the effects of an increased ALA intake, against an LA-rich background diet, on the carotid and femoral arterial wall intima-media thickness (IMT), and on oxidized LDL antibodies, soluble intercellular adhesion molecule-1, CRP, and interleukins 6 and 10 during 2 y of intervention.
Methods

Study design
The MARGARIN study, an acronym for Mediterranean Alpha linolenic enRiched Groningen dietARy Intervention study, is a coronary heart disease (CHD) prevention project for highrisk groups. The complete design is described elsewhere (Bemelmans et al, 2002) . In short, in a 2 Â 2 factorial design, we investigated the effects of two preventive interventions. First, the effects of a nutritional education programme (intervention group) were compared to a mailed leaflet (control group). Second, the effects of an increased intake of ALA were investigated against an LA-rich background diet. The effects of the two preventive interventions on established CHD risk factors have been published elsewhere (Bemelmans et al, 2002) . The present study aims to investigate the effects of increased ALA intake on markers of atherosclerosis and inflammation. No interference exists with the effects of the nutritional education programme, since we only included subjects from the intervention group (n ¼ 110). Due to budgetary reasons, the outcome parameters of the present study were measured in this group only.
In a double-blind study design, participants were randomly assigned to an ALA-enriched (n ¼ 55) or an LA-rich margarine (n ¼ 55). The ALA-enriched margarine contained 80% fat of which 21% saturated fatty acids (SFA), 18% monounsaturated fatty acids (MUFA), 46% LA, and 15% ALA. The LA-rich margarine contained 80% fat of which 23% SFA, 18% MUFA, 58% LA, and 0.3% ALA. Both margarines contained 66 mg vitamin E, 900 mg vitamin A, and 2.3 mg vitamin D, per 100 g. The project margarines could be used ad libitum. An independent Trial Coordination Centre allocated the margarines and organized the masked distribution during the study. The taste and the packaging of the margarines were identical. The medical ethical committee of the Groningen University Hospital approved the study protocol.
Informed consent was obtained from 110 persons, after which the margarines were randomly allocated. Seven subjects dropped out before the baseline examination in November 1997 (ALA: 4; LA: 3). Follow-up examinations were conducted after 1 and 2 y. The examinations consisted of collection of fasting blood samples, measurement of weight and blood pressure, and standardized questionnaires. All participants were investigated during a 2-week period in the local hospital. During the study, seven subjects dropped out (ALA: 3; LA: 4), and five persons missed one of the IMT assessments (ALA: 1; LA: 4). Hence, complete data were available for 47 and 48 users of the ALA and LA margarines, respectively.
Subjects
Eligible subjects were 30-70 y old, had a serum total cholesterol concentration between 6 and 8 mmol/l (mean of two separate measurements) and at least two of the following cardiovascular risk factors: high blood pressure (diastolic 495 mmHg and/or systolic 4160 mmHg) or use of antihypertensive medication, body mass index 427 kg/m 2 , smoking, history of cardiovascular disease or a family history of early onset of cardiovascular disease. The exclusion criteria were diabetes mellitus, hypothyroidism, and use of acetylsalicylic acid, anticoagulants, or cholesterol-lowering drugs. To identify potential participants, all inhabitants over 30 years of the intervention region were invited for a blood pressure screening programme. Second, registration systems of one general practitioner and three pharmacies were screened for patients on antihypertensive drugs. Third, a local radio programme invited potential participants to contact the research team.
Measurements
Body weight was measured without shoes and heavy clothing. Sitting blood pressure was measured after rest by an automatic device (Dinamap; Critikon Inc.,Tampa, FL, USA). Dietary intake was assessed by a self-administered semiquantitative food frequency questionnaire. The questionnaire consisted of 165 food items, 12 questions about added fat, and 10 questions about portion sizes. Consumption frequencies were reported per day, week or month. At baseline, Pearson's correlation coefficient of ALA intake as assessed by the questionnaire and the content of ALA in the cholesteryl ester was 0.37 (Po0.01) (Bemelmans et al, 2000) . Hence, the questionnaire assesses intake of ALA reasonably well.
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In fasting samples, serum total cholesterol was determined by enzymatic methods on a Vitros 950 (Ortho-Clinical Diagnostics, Rochester, NY, USA). Plasma fibrinogen was measured by the Clauss assay on an STA coagulation analyzer. For a sample containing 2.8 g/l the coefficient of variation was 3.6%. Serum CRP was assessed with a high-sensitivity CRP ELISA assay. Both intra-and interassay variation coefficients were 5%. Levels of IL-6 and IL-10 were analysed in the commercially available PeliKine Compact ELISA system (CLB, Amsterdam, The Netherlands). Serum samples were diluted two-fold for IL-6 and three-fold for IL-10. The same ELISAplate was used for duplicate samples of each patient. Concentrations were calculated from a standard curve ranging from 0 to 450 pg/ml IL-6 and from 0 to 300 pg/ml IL-10 and the respective dilution factors. Since only 14% of IL-6 and 4% of IL-10 results were above 1 pg/ml at baseline, we used the optical density (OD)-values as an alternative for the entire population. The OD reflects the amount of light that is absorbed by the sample. Interassay variation was eliminated by dividing the values by the third standard value that was assessed on each plate (for IL-6 50 pg/ml and IL-10 48 pg/ml). Antibodies to oxidized-LDL and native LDL were measured as described elsewhere (Swets et al, 2001) . Serum samples were diluted 1:25 times and the same ELISA-plate was used for triplicate samples of each patient. A standard serum arbitrarily set at 100 units, served as a reference. Results were first calculated as the mean OD obtained in the oxidized-LDLcoated plate minus the mean OD obtained in the LDL coated plate. Next, the results were translated into arbitrary units (AU) by relating the obtained oxLDLÀLDL (OD) values of the test samples to the oxLDLÀLDL (OD) value of the reference in the same ELISA-plate. Levels of sICAM-1 were measured by capture ELISA (HBT, Uden, The Netherlands) using a monoclonal antibody to sICAM-1 (HM.2) as capture antibody and a biotin-labelled anti-ICAM-1 as detection antibody, as described elsewhere (Wolkerstorfer et al, 1998) .
Assessment of IMT
The IMT was measured in the supine position with high resolution B-mode ultrasound images (ACUSON 128 XP, Mountain View, CA, USA) with a 7.0 MHz. linear array transducer, by the same sonographer, unaware of the clinical status of the patient. The right and left common carotid, carotid bulb, and the internal carotid arterial wall segments were imaged from a fixed lateral transducer angle. The common femoral and the superficial femoral arterial segments were imaged from a fixed anterior transducer angle. The common carotid arterial wall segment was defined as 1 cm proximal to the carotid dilatation, the carotid bulb as the segment between the carotid dilation and the carotid flow divider, the internal carotid segment as a 1-cm long arterial segment distal to the flow divider, the common femoral arterial segment as a 1-cm arterial segment proximal to the femoral dilatation, and the superficial femoral artery as the 1-cm arterial segment distal to the femoral flow divider. The arterial walls most distant from the transducer were imaged (far walls).
Scans of each arterial segment were stored in real-time mode on S-VHS videotapes for offline analysis, by an independent and blinded image analyst. From the B-mode images, single video frames were selected by the analyst for IMT measurements. The IMT is defined as the distance between the lumen/intima and the media/adventitia interfaces. Image analysis procedures and software are described elsewhere. A reliability was found of 0.75 for intersonographer variability and 0.88 for interanalist variability (de Groot et al, 1998 ). An IMT measurement of approximately 10 mm along the arterial wall was performed manually, by positioning markers along predefined edges of the near-and far-wall double-line patterns. The computer program subsequently drew lines through the markers.
The carotid and femoral arteries were investigated bilaterally at various segments. At each segment, we assessed the minimum, maximum and mean distance between the two interfaces of the far wall of the left and the right side divided by two, and the standard deviations. The data on combined IMT of the carotid and femoral artery were calculated by adding means of the various segments divided by three for the carotid artery and two for the femoral artery (average of mean values of all segments ¼ mean). Also data are shown on the mean of the maximum measurements of the arterial segments ( ¼ maximum).
Statistical analyses
At baseline, comparisons between ALA and LA groups were analysed for significant differences (Po0.05) with Student's ttest for normally distributed variables and w 2 test for categorical variables. The values of CRP, IL-6 and IL-10 were log transformed. Associations were assessed with the Pearson correlation coefficient or partial correlation coefficients adjusted for confounders. Changes during the study, within groups, were analysed with paired Student's t-test. Analysisof-covariance techniques were used to analyse differences between ALA and LA groups in changes of food intake, progression of IMT, and changes in markers of atherosclerosis and inflammation. All analyses were adjusted for the baseline level, and for confounding variables as indicated in the text. The CRP analyses were performed without persons having a value over 10 mg/l. The log-transformed CRP value after 1 or 2 y was the dependent variable, and as covariates we entered the log-2 transformed baseline value and use of cholesterollowering drugs. The analyses were performed with the statistical package SPSS 8.0 (SPSS Inc., Chicago, USA).
Results
Baseline characteristics and dietary intake At baseline, no significant differences existed in distribution of gender, mean age, dietary intakes, and established CHD risk factors between ALA and LA groups, except for a higher a-Linolenic acid, atherosclerosis and inflammation WJE Bemelmans et al concentration of serum total cholesterol in the LA group (Table 1) . Of the IL-6 and IL-10 levels only 14 and 4%, respectively, were above the detection limit of 1 pg/ml. During the study period, dietary intake of ALA was 2.3 en% (5.9 g/day) in the ALA group and 0.4 en% (1.0 g/day) in the LA group. The changes in other dietary habits were similar during a 2-y period (Table 2) .
Associations between the outcome parameters At baseline, the mean carotid IMT was positively associated with age (r ¼ 0. Table 3 shows baseline associations between the markers of atherosclerosis and inflammation.
Effects on the outcome parameters After 2 y, both ALA and LA groups showed an increase of 0.05 mm ( þ 6%) of the mean carotid IMT (when compared to baseline Po0.01), and the femoral IMT increased with 0.05 mm ( þ 6%) in the ALA group (NS), and 0.04 mm ( þ 5%) in the LA group (NS). Statistical adjustments for confounding variables did not appreciably alter the results (Table 4) . No significant differences existed between LA and ALA groups in progression of IMT. During 2 y, no significant changes were observed in concentrations of autoantibodies against oxLDL and sI-CAM-1 in both ALA and LA groups. With respect to inflammatory markers, the concentration of CRP was lower among ALA users as compared to LA users (net difference after 1 y ¼ À0.53 mg/l, and after 2 y ¼ À0.56 mg/l (Po0.05)), when adjusted for the baseline concentration and use of lipid-lowering medication, and exclusion of values above 10 mg/l. Within the ALA group, the median changes of CRP were À0.10 mg/l after 1 y and 0 after 2 y, and within the LA group these changes were þ 0.2 and þ 0.3 mg/l, respectively. No significant effects were observed for IL-6 and IL-10.
Discussion
Increased IMT is generally considered as a marker of subclinical atherosclerosis. The high cardiovascular risk character of our study group is reflected in the high IMT and CRP values for their age at baseline, and hence the population was suitable for this research. The 2-y progression rate of the carotid IMT (0.05 mm) is in line with previously a-Linolenic acid, atherosclerosis and inflammation WJE Bemelmans et al reported rates in the placebo arm of secondary prevention studies, where it varied between À0.02 and 0.034 mm/y. In these studies, the differences between statin and placebo groups varied between 0.01 and 0.03 mm/y (Ubels et al, 1999) . Our study may have been underpowered to exclude an effect of ALA on progression of IMT. However, because the observed IMT progression rate in both ALA and LA groups was comparable to that in the placebo arm of secondary prevention studies, we conclude that there is no evidence for a clinically significant antiatherogenic effect of ALA. This result is supported by Watts et al (1995) , who found no protective effects of ALA or eicosapentaenoic acid (EPA) on coronary artery narrowing, as assessed by quantitative coronary angiography (Watts et al, 1995) . The conclusion is also in line with the ARIC study which reported a positive, rather than an inverse, cross-sectional association between amount of eicosapentaenoic acid and ALA in the cholesterolester, and IMT (Ma et al, 1997) .
Besides the limited power of this study, since this manuscript does not include the primary outcome parameter, for example, plasma ALA content (Bemelmans et al, 2002) and we used data from the intervention group only, other limitations are acknowledged. Despite the stratified randomization procedure, baseline differences existed in serum total cholesterol and CRP (not significant) among ALA and LA users. However, all statistical analyses were adjusted for the baseline value to minimize confounding effects of regression to the mean. Since the individual concentration of CRP can be highly variable, and very high values probably indicate a major infection or trauma (Ridker, 2003) , persons with values over 10 mg/l were excluded. Unfortunately, the vast majority of IL-6 and IL-10 values were below the detection limit, and the OD ratios were used as an alternative. Table 3 shows that associations with the other parameters are as expected, but nevertheless our IL-6 and IL-10 results should be interpreted with caution. A strength of our study is that we could check compliance in using the Table 2 Changes in dietary intake after 2 y, as assessed by food frequency questionnaire, stratified for type of margarine Changes after 2 y a (mean (s.e.m))
Energy (MJ/day) 10.0 (3.2) À0.5 (0.3) À0.6 (0.3) Total fat (en%) 37.6 (6.9) À0.6 (0.8) À0.9 (0.8) Saturated fat (en%) 14.0 (3.0)
20.9 (10.0) þ 3.0 (1.6) þ 4.6 (1.5) Ratio LA/ALA 17.1 (7.9)
52 (26) À4 ( a-Linolenic acid, atherosclerosis and inflammation WJE Bemelmans et al margarines by the fatty acid profile of the cholesteryl ester. As expected, the ALA margarine increased contents of ALA, EPA and n-3/n-6 ratio, so compliance in using the margarines was good (Bemelmans et al, 2002) . Regarding the pathogenesis of atherosclerosis the response-to-injury theory proposes that cardiovascular risk factors can have adverse effects on the vascular wall. Hereby, a number of functional changes to the endothelium are triggered, which is called endothelial dysfunction. This is present in an early stage and is characterized, among others, by increased expression of cellular adhesion molecules (Ross, 1999) . Atherosclerosis is nowadays considered a low-grade inflammatory disease, and oxidized LDL is one of the most important triggers of an inflammatory response (Glass and Witztum, 2001) . The CRP concentration reflects inflammation, and has been shown to be independently predictive for the occurence of adverse events in patients with various atherosclerotic diseases . It is believed that modulation of the inflammatory response may reduce atherosclerotic disease (Libby, 2002) .
Previous research regarding effects of increased ALA intake on atherosclerosis and inflammation is scarce. Some studies, that supplemented daily doses of 14-18 g of ALA a day, showed effects on endothelial function, but others that supplemented lower doses did not (Sanderson et al, 2002) . Both EPA and ALA have been shown to decrease the synthesis of cytokines (Mantzioris et al, 2000; De Caterina & Basta, 2001) . Rallidis et al (2003) found, in a population similar to ours, a lower level of CRP with a 3-month increased intake of ALA. This finding is confirmed by the present results, with a similar intake of ALA of around 6-8 g/day. Furthermore, data using the complete MARGARIN study population showed a significantly lower level of fibrinogen (Bemelmans et al, 2002) . Hennig et al (2000) showed that LA increased expression of interleukin-6 while ALA supplementation had no impact. This can explain the mechanism behind the effects of ALA on fibrinogen and CRP, since IL-6 may act on hepatocytes to induce acutephase reactants (Gabay and Kushner, 1999) . Indeed, Rallidis et al found lower IL-6 levels with increased ALA intake. Our analyses, however, showed no effects on IL-6 or IL-10 whatsoever, but this could be due to the laboratory technique. Probably, the test that was used by Rallidis et al was more accurate in detecting IL-6 since their patients a-Linolenic acid, atherosclerosis and inflammation WJE Bemelmans et al exceeded the detection limit of 1 pg/ml in contrast with the majority of the present population.
In the secondary prevention of CHD, both fish and ALA have been suggested to be preventive (de Lorgeril et al, 1994; Marchioli et al, 2001) . Because of the lower CRP level, the present results suggest that a six-fold increased ALA intake may have anti-inflammatory effects, when investigated against an LA-rich background diet. However, an ALA intake of 6 g/day is hard to achieve by a conventional Dutch diet. Furthermore, our results regarding IMT and atherosclerotic markers do not confirm that the cardioprotective effects of ALA are primarily mediated by an antiatherogenic action.
